Evidence map›Paper›PMID 25972260›Full record

Trial reportOphthalmology2015

Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.

Peter A Campochiaro, Gulnar Hafiz, Tahreem A Mir, Adrienne W Scott, Sharon Solomon, Ingrid Zimmer-Galler, Akrit Sodhi, Elia Duh, Howard Ying, Adam Wenick and 5 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04062370 (Different Regimens of Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion), which is not on this map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04062370 phase4unknown statusnot on this mapstarted 2019, after this paper: background citation

Different Regimens of Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion: a Randomized and Controlled Clinical Study.

TypeinterventionalSponsorSun Yat-sen UniversityRan2019 to 2022Enrolled100ConditionsRetinal Vein Occlusion, Treatment, Photocoagulation Burn to Retina, RanibizumabArmsRanibizumab, laser photocoagulation
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Peter A CampochiaroThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: pcampo@jhmi.edu.
Gulnar HafizThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Tahreem A MirThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Adrienne W ScottThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sharon SolomonThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ingrid Zimmer-GallerThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Akrit SodhiThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Elia DuhThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Howard YingThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Adam WenickThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Syed Mahmood ShahThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Diana V DoThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Quan D NguyenThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Saleema KheraniThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Raafay SophieThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Divergent Roles for Hypoxia-Inducible Factor-1 and -2 in Ischemic Retinal DiseaseR01EY029750 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2019 to 2023
$2.6M
HIF dysregulation as a novel genetic model to study retinal neovascular disease.K08EY021189 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2011 to 2015
$898k
NEI NIH HHS K08 EY021189NEI NIH HHS R01 EY029750
6 · The paper itself

Abstract

purposeTo determine whether scatter and grid laser photocoagulation (laser) adds benefit to ranibizumab injections in patients with macular edema from retinal vein occlusion (RVO) and to compare 0.5-mg with 2.0-mg ranibizumab.

designRandomized, double-masked, controlled clinical trial.

participantsThirty-nine patients with central RVO (CRVO) and 42 with branch RVO (BRVO).

methodsSubjects were randomized to 0.5 mg or 2.0 mg ranibizumab every 4 weeks for 24 weeks and re-randomized to pro re nata ranibizumab plus laser or ranibizumab alone.

main outcome measuresMean change from baseline best-corrected visual acuity (BCVA) at week 24 for BCVA at weeks 48, 96, and 144 for second randomization.

resultsMean improvement from baseline BCVA at week 24 was 15.5 and 15.8 letters in the 0.5-mg and 2.0-mg CRVO groups, and 12.1 and 14.6 letters in the 0.5-mg and 2.0-mg BRVO groups. For CRVO, but not BRVO, there was significantly greater reduction from baseline mean central subfield thickness (CST) in the 2.0-mg versus 0.5-mg group (396.1 vs. 253.5 μm; P = 0.03). For the second randomization in CRVO patients, there was no significant difference from week 24 BCVA in the ranibizumab plus laser versus the ranibizumab only groups at week 48 (-3.3 vs. 0.0 letters), week 96 (+0.69 vs. -1.6 letters), or week 144 (+0.4 vs. -6.7 letters), and a significant increase from week 24 mean CST at week 48 (+94.7 vs. +15.2 μm; P = 0.05) but not weeks 96 or 144. For BRVO, there was a significant reduction from week 24 mean BCVA in ranibizumab plus laser versus ranibizumab at week 48 (-7.5 vs. +2.8; P < 0.01) and week 96 (-2.0 vs. +4.8; P < 0.03), but not week 144, and there were no differences in mean CST change from week 24 at weeks 48, 96, or 144. Laser failed to increase edema resolution or to reduce the ranibizumab injections between weeks 24 and 144.

conclusionsIn patients with macular edema resulting from RVO, there was no short-term clinically significant benefit from monthly injections of 2.0-mg versus 0.5-mg ranibizumab injections and no long-term benefit in BCVA, resolution of edema, or number of ranibizumab injections obtained by addition of laser treatment to ranibizumab.

Indexed as

Laser CoagulationAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedCombined Modality TherapyDouble-Blind MethodFemaleHumansIntravitreal InjectionsMacular EdemaMaleMiddle AgedRanibizumabRetinal Vein OcclusionTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedRanibizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID25972260
PMCPMC10020833
OpenAlexW2214801776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.